BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28432387)

  • 1. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma.
    Chan LS; Sze DY; Poultsides GA; Louie JD; Abdelrazek Mohammed MA; Wang DS
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1383-1391. PubMed ID: 28432387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
    Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
    PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 7. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
    Saxena A; Bester L; Chua TC; Chu FC; Morris DL
    Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports.
    Carvalho VO; Galastri FL; Affonso BB; Falsarella PM; Valle LGM; Ferraz-Neto BH; Rezende MB; Motta-Leal-Filho JMD; Garcia RG; Nasser F
    Einstein (Sao Paulo); 2020; 18():eRC4990. PubMed ID: 32130329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.
    Rayar M; Sulpice L; Edeline J; Garin E; Levi Sandri GB; Meunier B; Boucher E; Boudjema K
    Ann Surg Oncol; 2015 Sep; 22(9):3102-8. PubMed ID: 25623598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.
    Kim DY; Park BJ; Kim YH; Han KH; Cho SB; Cho KR; Uhm SH; Choe JG; Choi JY; Chun HJ; Lee HC; Gwon DI; Lee KH; Yoon JH; Chung JW; Kim CW; Heo J; Kim JK; Joo YE
    Am J Clin Oncol; 2015 Oct; 38(5):495-501. PubMed ID: 24064753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.
    Al-Adra DP; Gill RS; Axford SJ; Shi X; Kneteman N; Liau SS
    Eur J Surg Oncol; 2015 Jan; 41(1):120-7. PubMed ID: 25449754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival.
    Swinburne NC; Biederman DM; Besa C; Tabori NE; Fischman AM; Patel RS; Nowakowski FS; Gunasekaran G; Schwartz ME; Lookstein RA; Kim E
    Cancer Biother Radiopharm; 2017 Jun; 32(5):161-168. PubMed ID: 28598685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma.
    Saboo SS; Krajewski KM; Jagannathan JP; O'Regan KN; Odze R; Ramaiya N; Wolpin BM
    Cancer Imaging; 2011 Mar; 11(1):37-41. PubMed ID: 21507775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Treatment with
    Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
    [No Abstract]   [Full Text] [Related]  

  • 20. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
    Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.